NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Bioanalytical Testing Services Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and co ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...

Meanwhile, WuXi Vaccines, a subsidiary of WuXi Biologics, says it will sell a vaccine facility in Dundalk, Ireland, to the US drugmaker Merck & Co. for $521 million. WuXi Biologics says the sale ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co. for approximately USD 500 million. The decision comes ahead of potential U.S ...

(Borrell, 1/7) Reuters: China's WuXi Biologics To Sell Irish Vaccine Facility To Merck As US Curbs Loom China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S.

WuXi Biologics (HKEX: 2269), today announced a definitive agreement with Merck & Co’s (NYSE: MRK) MSD International GmbH unit, whereby the latter will acquire WuXi Vaccines’ facility in Dundalk, ...

Although the newsthat WuXi Bio sold its Ireland vaccine facility to Merck (MRK) for about $500M sent the stock lower, the firm thinks the company sold the facility not mainly due to “Biosecure ...

Meanwhile, China's WuXi Biologics intends to sell its Irish vaccine facility to Merck & Co for $500 million, ahead of impending U.S. legislation restricting Chinese biotech firms' operations. The ...